Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product ...

FDA approvals in 2025 introduced novel therapies and devices across ophthalmic subspecialties, emphasizing sustained efficacy ...

LENZ Therapeutics (LENZ) announced an exclusive distribution agreement for Lunatus to register and commercialize VIZZ for the ...

Multi-asset pipeline with significant targeted data readouts and milestones -- Two lead ophthalmic gene therapy programs in clinical trials ...

Exclusive distribution agreement includes revenue sharing in addition to upfront and milestone payments to LENZ ...

Launched VIZZ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025 Achieved approximately $1.6 million in net pr ...

Lake Oswego, OR - January 08, 2026 - PRESSADVANTAGE - At Tersigni Vision, a growing number of patients are asking ...

Opus Genetics (IRD) highlighted its progress achieved during 2025 and upcoming catalysts in 2026. OPGx-BEST1: First ...

As people age, their eyes change, making it important to stay informed about eye health. Many vision issues are manageable ...

In 2025, the FDA approved 73 first-time generic drugs.  Here are the generics and their indication, in order of approval date: Note: The FDA’s information is current as of Dec. 18. 1. Phytonadione ...

SAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced that Lotus ...

Detailed price information for Opus Genetics Inc (IRD-Q) from The Globe and Mail including charting and trades.